1009 related articles for article (PubMed ID: 24013361)
1. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study.
Paul S; Del Tedesco E; Marotte H; Rinaudo-Gaujous M; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Roblin X
Inflamm Bowel Dis; 2013 Nov; 19(12):2568-76. PubMed ID: 24013361
[TBL] [Abstract][Full Text] [Related]
2. The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease.
Hoekman DR; Brandse JF; de Meij TG; Hummel TZ; Löwenberg M; Benninga MA; D'Haens GR; Kindermann A
Scand J Gastroenterol; 2015; 50(9):1110-7. PubMed ID: 25865965
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study.
Warman A; Straathof JW; Derijks LJ
Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):242-8. PubMed ID: 25569569
[TBL] [Abstract][Full Text] [Related]
4. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease.
Schnitzler F; Fidder H; Ferrante M; Noman M; Arijs I; Van Assche G; Hoffman I; Van Steen K; Vermeire S; Rutgeerts P
Inflamm Bowel Dis; 2009 Sep; 15(9):1295-301. PubMed ID: 19340881
[TBL] [Abstract][Full Text] [Related]
5. Dosing interval and diagnosis predict infliximab levels in patients with inflammatory bowel disease on maintenance treatment.
Krajcovicova A; Batovsky M; Gregus M; Hlista M; Durina J; Leskova Z; Sturdik I; Gojdic M; Jalali Y; Koller T; Toth J; Huorka M; Hlavaty T
Acta Gastroenterol Belg; 2018; 81(4):465-470. PubMed ID: 30645913
[TBL] [Abstract][Full Text] [Related]
6. One-Year Clinical Outcomes in an IBD Cohort Who Have Previously Had Anti-TNFa Trough and Antibody Levels Assessed.
Tighe D; Hall B; Jeyarajah SK; Smith S; Breslin N; Ryan B; McNamara D
Inflamm Bowel Dis; 2017 Jul; 23(7):1154-1159. PubMed ID: 28486256
[TBL] [Abstract][Full Text] [Related]
7. Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre.
Kolar M; Duricova D; Bortlik M; Hruba V; Machkova N; Mitrova K; Malickova K; Lukas M; Lukas M
Dig Dis; 2017; 35(1-2):91-100. PubMed ID: 28147356
[TBL] [Abstract][Full Text] [Related]
8. Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab.
Orfanoudaki E; Gazouli M; Foteinogiannopoulou K; Theodoraki E; Legaki E; Romanos I; Mouzas I; Koutroubakis IE
Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):187-191. PubMed ID: 30543573
[TBL] [Abstract][Full Text] [Related]
9. Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease.
Singh N; Rosenthal CJ; Melmed GY; Mirocha J; Farrior S; Callejas S; Tripuraneni B; Rabizadeh S; Dubinsky MC
Inflamm Bowel Dis; 2014 Oct; 20(10):1708-13. PubMed ID: 25153505
[TBL] [Abstract][Full Text] [Related]
10. Causes of Treatment Failure in Children With Inflammatory Bowel Disease Treated With Infliximab: A Pharmacokinetic Study.
Naviglio S; Lacorte D; Lucafò M; Cifù A; Favretto D; Cuzzoni E; Silvestri T; Pozzi Mucelli M; Radillo O; Decorti G; Fabris M; Bramuzzo M; Taddio A; Stocco G; Alvisi P; Ventura A; Martelossi S
J Pediatr Gastroenterol Nutr; 2019 Jan; 68(1):37-44. PubMed ID: 30211845
[TBL] [Abstract][Full Text] [Related]
11. Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn's disease under infliximab therapy.
Cao WT; Huang R; Liu S; Fan YH; Xu MS; Xu Y; Ni H
World J Gastroenterol; 2022 Jun; 28(23):2582-2596. PubMed ID: 35949356
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of infliximab biosimilar CT-P13 in treating ulcerative colitis: a real‑life experience in IBD primary centers.
Tursi A; Allegretta L; Chiri S; Della Valle N; Elisei W; Forti G; Lorenzetti R; Mocci G; Penna A; Pranzo G; Ricciardelli C; Picchio M
Minerva Gastroenterol Dietol; 2017 Dec; 63(4):313-318. PubMed ID: 28293938
[TBL] [Abstract][Full Text] [Related]
13. [The diagnostic and evaluation value of plasma interleukin 9 in the mucosal healing in patients with inflammatory bowel disease treated with biological agents].
Ye YL; Hu T; Xu LJ; Zhang LP; Yin J; Yu Q; Pang Z
Zhonghua Yi Xue Za Zhi; 2023 May; 103(19):1483-1489. PubMed ID: 37198111
[No Abstract] [Full Text] [Related]
14. INFLIXIMAB AND ADALIMUMAB SERUM TROUGH CONCENTRATIONS THRESHOLD ASSOCIATED WITH DEEP REMISSION IN INFLAMMATORY BOWEL DISEASE.
Pascual-Marmaneu Ó; Belles-Medall MD; Ferrando-Piqueres R; Almela-Notari P; Mendoza-Aguilera M; Álvarez-Martín T
Farm Hosp; 2021 Aug; 45(5):225-233. PubMed ID: 34806581
[TBL] [Abstract][Full Text] [Related]
15. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
Chaparro M; Barreiro-de Acosta M; Echarri A; Almendros R; Barrio J; Llao J; Gomollón F; Vera M; Cabriada JL; Guardiola J; Guerra I; Beltrán B; Roncero O; Busquets D; Taxonera C; Calvet X; Ferreiro-Iglesias R; Ollero Pena V; Bernardo D; Donday MG; Garre A; Godino A; Díaz A; Gisbert JP
Dig Dis Sci; 2019 Mar; 64(3):846-854. PubMed ID: 30426297
[TBL] [Abstract][Full Text] [Related]
16. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease.
Steenholdt C; Bendtzen K; Brynskov J; Thomsen OØ; Munck LK; Christensen LA; Pedersen G; Kjeldsen J; Ainsworth MA
J Crohns Colitis; 2015 Mar; 9(3):238-45. PubMed ID: 25576753
[TBL] [Abstract][Full Text] [Related]
17. Higher Serum Infliximab Concentrations Following Subcutaneous Dosing are Associated with Deep Remission in Patients with Inflammatory Bowel Disease.
Roblin X; Nancey S; Papamichael K; Duru G; Flamand M; Kwiatek S; Cheifetz A; Fabien N; Barrau M; Paul S
J Crohns Colitis; 2024 May; 18(5):679-685. PubMed ID: 37934041
[TBL] [Abstract][Full Text] [Related]
18. Clinical Use of Infliximab Trough Levels and Antibodies to Infliximab in Pediatric Patients With Inflammatory Bowel Disease.
Merras-Salmio L; Kolho KL
J Pediatr Gastroenterol Nutr; 2017 Feb; 64(2):272-278. PubMed ID: 27149256
[TBL] [Abstract][Full Text] [Related]
19. Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease.
van Hoeve K; Dreesen E; Hoffman I; Van Assche G; Ferrante M; Gils A; Vermeire S
J Crohns Colitis; 2018 Nov; 12(11):1316-1325. PubMed ID: 30239644
[TBL] [Abstract][Full Text] [Related]
20. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
Ferrante M; Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens GR; van der Woude CJ; Danese S; Diamond RH; Oortwijn AF; Tang KL; Miller M; Cornillie F; Rutgeerts PJ;
Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
